Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome
Keywords:
Metformin, Anti-Mullerian hormone, Polycystic ovary syndrome, InfertilityAbstract
Background: Polycystic ovary syndrome (PCOS) is the major cause of anovulatory infertility in women. The level of serum Anti-Mullerian Hormone (AMH) in patients can be 2-3 times higher than in healthy women. The aim of this study was to assess the effect of metformin on AMH level in PCOS patients suffering from infertility. Methods: In this pre and post clinical trial, 30 infertile patients with PCOS were enrolled according to the Rotterdam criteria. The serum AMH level was recorded before and after 8 weeks of treatment with metformin (1500 mg daily). We used SPSS version 17 and paired samples t-test, multiple linear regression and ANCOVA test for data analysis. Results: Serum AMH level was significantly decreased after 8 weeks of treatment with metformin [10±3.75 (ng/ml) versus 7.8±3.7 (ng/ml)] (p=0.008, 95% CI: 0.60-3.75). Also, AMH level change was directly associated to BMI in PCOS patients. In other words, in these patients, a higher BMI led to more decrease in AMH level after metformin treatment. Conclusion: Eight weeks’ treatment with metformin would significantly decrease AMH. AMH level change was directly associated to BMI. Clinical trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: 201403132967N5 Funding: This study was funded by the Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences (Grant Number: 9322).References
Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens,
insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without
polycystic ovary syndrome. HumReprod. 2009; 24(11): 2917-23. doi: 10.1093/humrep/dep225. PMID:
Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti- mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess
and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12): 5957-62. doi: 10.1210/jc.2003-030727.
PMID: 14671196.
Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum
concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab.
, 89(1): 318-23. doi: 10.1210/jc.2003-030932. PMID: 14715867.
Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti- Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in
women with polycystic ovary syndrome. Hum Reprod. 2005; 20(7): 1820-6. doi: 10.1093/humrep/deh850.
PMID: 15802325.
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, et al. Metformin reduces serum
mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
Fertil Steril. 2005; 83(1): 130-6. doi: 10.1016/j.fertnstert.2004.05.098. PMID: 15652898.
Neagu M, Cristescu C. Anti-Mullerian hormone--a prognostic marker for metformin therapy efficiency in
the treatment of women with infertility and polycystic ovary syndrome. J Med Life. 2012; 5(4): 462-4.
PMID: 23346251, PMCID: PMC3539844.
Grigoryan O, Absatarova J, Andreeva E, Melnichenko G, Dedov I. Effect of metformin on the level of anti- Mullerian hormone in therapy of polycystic ovary syndrome in obese women. Minerva Ginecol. 2014;
(1): 85-9. PMID: 24569407.
Madsen HN, Lauszus FF, Trolle B, Ingerslev HJ, Torring N. Impact of metformin on anti-Mullerian
hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
Acta Obstet Gynecol Scand. 2015; 94(5): 547-51. doi: 10.1111/aogs.12605. PMID: 25736975.
Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and
idiopathic hirsutism. Br Med J (Clin Res Ed). 1986; 293(6543): 355-9. PMID: 3089520, PMCID:
PMC1341046.
Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Mullerian-inhibiting substance in follicular fluid and
serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis.
Fertil Steril. 1997; 67(5): 962-5. PMID: 9130910.
Kezele PR, Nilsson EE, Skinner MK. Insulin but not insulin-like growth factor-1 promotes the primordial
to primary follicle transition. Mol Cell Endocrinol. 2002; 192(1-2): 37-43. PMID: 12088865.
Gulyas BJ, Hodgen GD, Tullner WW, Ross GT. Effects of fetal or maternal hypophysectomy on endocrine
organs and body weight in infant rhesus monkeys (Macacamulatta): with particular emphasis on oogenesis.
Biol Reprod. 1977; 16(2): 216-27. PMID: 401655.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for
pathogenesis. Endocr Rev. 1997; 18(6): 774-800.
Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction.
; 132(2): 191-206.
Nascimento AD, Silva Lara LA, Japur de Sá Rosa-e-Silva AC, Ferriani RA, Reis RM. Effects of metformin
on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic
ovary syndrome. Gynecol Endocrinol. 2013; 29(3): 246-9. doi: 10.3109/09513590.2012.736563. PMID:
Kriseman M, Mills C, Kovanci E, Sangi-Haghpeykar H, Gibbons W. Antimullerian hormone levels are
inversely associated with bodymass index (BMI) in women with polycystic ovary syndrome. J Assist
Reprod Genet. 2015; 32(9): 1313-6. doi: 10.1007/s10815-015-0540-0. PMID: 26238387, PMCID:
PMC4595400.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
